Drug use in acute meningococcal disease

Archives of Disease in Childhood: Education and Practice Edition

Volumn 93, Issue 5, 2008, Pages 151-158

  Cathie, K ^a   Levin, M ^b   Faust, S N ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CORTICOSTEROID; DEXAMETHASONE; DOBUTAMINE; DOPAMINE; FRESH FROZEN PLASMA; FUROSEMIDE; GLYCEROL; HYDROCORTISONE; INOTROPIC AGENT; LIDOCAINE; MANNITOL; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; NORADRENALIN; PENICILLIN G; PROTEIN C; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RIFAMPICIN; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN K GROUP;

ANTIBIOTIC THERAPY; CORTICOSTEROID THERAPY; EPIDEMIC MENINGITIS; HUMAN; MENINGOCOCCOSIS; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SINGLE DRUG DOSE;

ANTI-BACTERIAL AGENTS; CEFOTAXIME; CHILD, PRESCHOOL; DISSEMINATED INTRAVASCULAR COAGULATION; FLUID THERAPY; HUMANS; INTRACRANIAL HYPERTENSION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; SEPSIS;

EID: 53549084345     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/adc.2007.127696     Document Type: Review

References (58)

1. Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001;85(5):386-90.
2. Thorburn K, Baines P, Thomson A, et al. Mortality in severe meningococcal disease. Arch Dis Child 2001;85(5):382-5.
3. Paedriatric Intensive Care Audit Network. See www.picanet. org.uk (accessed 5 August 2008).
4. Health Protection Agency. Meningococcal disease. Epidemiological data. See http://www.hpa.org.uk/webw/ HPAweb&Page& HPAwebAutoListName/Page/ 1201094595391?p=1201094595391 (accessed 5 August 2008).
5. CDC. Centers for disease control and prevention: morbidity and mortality weekly report (MMWR), 2008. See www.cdc.gov/ mmwr/PDF/wk/mm5553.pdf for 2006 data and www.cdc.gov/ mmwr/preview/mmwrhtml/mm5652md.htm for 2007 data (both accessed 13 August 2008).
6. Health Protection Agency. Invasive meningococcal infections, England and Wales, laboratory reports: weeks 51-52/2007. Available from http://www.hpa.org.uk/hpr/archives/2008/hpr0808. pdf (accessed 5 August 2008).
7. Health Protection Agency. Guidance for the public health management of meningococcal disease in the UK, 2006. Available from http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/ 1194947389261 (accessed 5 August 2008)
8. Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989;159(2):195-204.
9. Matheson NJ, Symmonds-Abrahams M, Sheikh A, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2003;(3):CD002744.
10. NICE. Feverish illness in children - Assessment and initial management in children younger than 5 years. London: NICE, 2007. Available from http://www.nice.org.uk/cg047 (accessed 5 August 2008).
11. FDA. Ceftriaxone (marketed as Rocephin) information. Available from http://www.fda.gov/Cder/drug/infopage/ceftriaxone/default. htm (accessed 5 August 2008).
12. Roche. Important clarification of prescribing information. Contraindications. August 2007. http://www.rocheusa.com/ products/rocephin/ rocephin-hcp-letter.pdf (accessed 5 August 2008)
13. MHRA. Ceftriaxone: incompatibility with calcium-containing solutions. Drug Safety Update 2007;1(4):5. Available from www. nelm.nhs.uk/en/NeLM-Area/Evidence/Adverse-Effects-And-Their-Prevention/500923 (accessed 13 August 2008).
14. Pollard AJ, Nadel S, Ninis N, et al. Emergency management of meningococcal disease: eight years on. Arch Dis Child 2007;92(4):283-6.
15. Fraser A, Gafter-Gvili A, Paul M, et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 2005;(1):CD004785.
16. Fraser A, Gafter-Gvili A, Paul M, et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 2006;(4):CD004785.
17. Clark J, Lakshman R, Galloway A, et al. Does cefotaxime eradicate nasopharyngeal carriage of N meningiditis. Arch Dis Child 2002;87(5):449.
18. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 1998;316(7136):961-4.
19. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350(22):2247-56.
20. Nadel S, De Munter C, Britto J, et al. Albumin: saint or sinner? Arch Dis Child 1998;79(5):384-5.
21. Meningitis Research Foundation. Early management of meningococcal disease in children. Available from http://www. meningitis.org/assets/x/50150 (accessed 5 August 2008)
22. Vincent JL, Abraham E, Annane D, et al. Reducing mortality in sepsis: new directions. Crit Care 2002;6(Suppl 3):S1-18.
23. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004;363(9404):203-9.
24. Ninis N, Phillips C, Bailey L, et al. The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases. BMJ 2005; 330(7506):1475.
25. Ceneviva G, Paschall JA, Maffei F, et al. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998;102(2):e19.
26. Carcillo JA, Fields Al. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002;30(6):1365-78.
27. Faust S, Heyderman R, Levin M. Disseminated intravascular coagulation and purpura fulminans secondary to infection. Baillieres Best Pract Res Clin Haematol 2000;13(2):179-97.
28. Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000;356(9234):961-7.
29. Powars DR, Rogers ZR, Patch MJ, et al. Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S [letter]. N Engl J Med 1987;317(9):571-2.
30. Leclerc F, Hazelzet J, Jude B, et al. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 1992;18(4):202-5.
31. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-709.
32. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369(9564):836-43.
33. FDA. Discontinuation of study FIK-MC-EVBP, Investigation of the efficacy and safety of drotrecogin alfa (activated) in pediatric severe sepsis. 2005. Available from http://www.fda.gov/ medwatch/SAFETY/2005/xigris_dearHCP_4- 21 -05.htm (accessed 5 August 2008).
34. Zenz W, Zoehrer B, Levin M, et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med 2004;32(8):1777-80.
35. Kulkarni S, Naureckas E, Cronin DC 2nd. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003;75(6):899-901.
36. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Eng J Med 1987;317(11):653-8.
37. Bone M, Diver M, Selby A, et al. Assessment of adrenal function in the initial phase of meningococcal disease. Pediatrics 2002;110(3):563-9.
38. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71.
39. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358(2):111-24.
40. de Groof F, Joosten KF, Janssen JA, et al. Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J Clin Endocrinol Metab 2002;87(7):3118-24.
41. Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 1999;28(4):770-7.
42. Mok Q, Butt W. The outcome of children admitted to intensive care with meningococcal septicaemia. Intensive Care Med 1996;22(3):259- 63.
43. Goldman AP, Kerr SJ, Butt W, et al. Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 1997:349(9050):466-9.
44. Pearson G, Khandelwal PC, Naqvi N. Early filtration and mortality in meningococcal septic shock? Arch Dis Child 2000;83(6):508-9.
45. Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, et al. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 2006:10(1):R20.
46. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008:358(9):877-87.
47. Pathan N, Williams EJ, Oragui EE, et al. Changes in the interleukin-6/soluble interleukin-6 receptor axis in meningococcal septic shock. Crit Care Med 2005;33(8): 1839-44.
48. Tunkel AH, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993;6(2):118-36.
49. Ganesan V, Kelsey H, Cookson J, et al. Activated protein C resistance in childhood stroke. Lancet 1996:347(8996):260.
50. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjsunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997:278(11):925-31.
51. van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007:(1):CD004405.
52. Greenwood BM. Corticosteroids for acute bacterial meningitis. N Engl J Med 2007:357(24):2507-9.
53. Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007:45(10):1277-86.
54. Banner P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002;51(9):717-22.
55. Turner GD, Ly VC, Nguyen TH, et al. Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol 1998;152(6):1477-87.
56. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299(2):173-84.
57. Zimmer SM, Stephens DS. Serogroup B meningococcal vaccines Curr Opin Investig Drugs 2006;7(8):733-9.
58. Paediatric Formulary Committee. BNF for children 2007. London: BMJ Publishing Group, RPS Publishing and RCPCH Publications, 2007.